Medications That Affect 123I-MIBG Imaging (13)
Drug or class | Examples | Mechanism of interference (known or expected) | Discontinuation before 123I-MIBG scan (d) |
Opioid | Uptake inhibition | 7–14 | |
Cocaine | Uptake inhibition | 7–14 | |
Tramadol | Uptake inhibition | 7–14 | |
Tricyclic antidepressants | Amitriptyline and derivatives, imipramine and derivatives, amoxapine, doxepin, others | Uptake inhibition | 7–21 |
Sympathicomimetics * | Phenylpropanolamine, ephedrine, pseudoephedrine, phenylephrine, amphetamine, dopamine, isoproterenol, salbutamol, terbutaline, fenoterol, xylometazoline | Depletion of granules | 7–14 |
Antihypertensive or cardiovascular agents | Labetalol | Inhibition of uptake and depletion | 21 |
Reserpine | Depletion and transport inhibition | 14 | |
Bretylium, guanethidine | Depletion and transport inhibition | 14 | |
Calcium channel blockers (nifedipine, nicardipine, amlodipine) | Increased uptake and retention | 14 | |
Antipsychotics | Phenothiazines † (chlorpromazine, promethazine, fluphenazine, others) | Uptake inhibition | 21–28 |
Thioxanthenes (maprotiline, trazodone) | Uptake inhibition | 21–28 | |
Butyrophenones (droperidol, haloperidol) | Uptake inhibition | 21–28 | |
Loxapine | Uptake inhibition | 7–21 |